Impact of time to diagnosis in patients with primary Sjögren's syndrome: a cross-sectional study.

IF 3.4 4区 医学 Q2 RHEUMATOLOGY Clinical and experimental rheumatology Pub Date : 2024-12-01 Epub Date: 2024-12-03 DOI:10.55563/clinexprheumatol/karr2a
Anna Meinecke, Kristine Kreis, Paul Olson, Juliana R Hoeper, Fiona Engelke, Tabea Seeliger, Thomas Skripuletz, Diana Ernst, Kirsten Hoeper, Torsten Witte
{"title":"Impact of time to diagnosis in patients with primary Sjögren's syndrome: a cross-sectional study.","authors":"Anna Meinecke, Kristine Kreis, Paul Olson, Juliana R Hoeper, Fiona Engelke, Tabea Seeliger, Thomas Skripuletz, Diana Ernst, Kirsten Hoeper, Torsten Witte","doi":"10.55563/clinexprheumatol/karr2a","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Primary Sjögren's syndrome is a chronic autoimmune disease with an inflammation of exocrine glands. It can be difficult to diagnose due to frequently unspecific symptoms, such as fatigue and myalgia. The aim of this study was to investigate the journey of patients prior to the diagnosis of primary Sjögren's syndrome and how this affects the patient-reported outcomes.</p><p><strong>Methods: </strong>The study included 170 patients from the outpatient clinic with an age of at least 18 years that were diagnosed with primary Sjögren's syndrome (ICD-10 M35.0) and fulfilled ACR/EULAR 2016 criteria at least 12 months before. Socio-demographic details, patient-reported outcomes and the history of diagnosis were obtained via a structured questionnaire.</p><p><strong>Results: </strong>The average diagnostic latency for this group of patients with Sjögren's syndrome is 5.98 years, with a median of 2 years. The cohort was divided into two groups based on the median of two years: one with a longer and the other with a shorter diagnostic delay. The group with a longer diagnostic delay was in a significantly poorer general health condition and was significantly more likely to report a negative impact on the general performance. Patients with longer diagnostic delay reported significantly more physician visits and suffered significantly more frequently from vaginal dryness, gastrointestinal symptoms and breathlessness as initial symptoms.</p><p><strong>Conclusions: </strong>Our findings underline the importance of awareness of Sjögren's syndrome and interdisciplinary training of physicians to improve the patient related outcomes due to a reduced diagnostic latency.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"2444-2452"},"PeriodicalIF":3.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55563/clinexprheumatol/karr2a","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Primary Sjögren's syndrome is a chronic autoimmune disease with an inflammation of exocrine glands. It can be difficult to diagnose due to frequently unspecific symptoms, such as fatigue and myalgia. The aim of this study was to investigate the journey of patients prior to the diagnosis of primary Sjögren's syndrome and how this affects the patient-reported outcomes.

Methods: The study included 170 patients from the outpatient clinic with an age of at least 18 years that were diagnosed with primary Sjögren's syndrome (ICD-10 M35.0) and fulfilled ACR/EULAR 2016 criteria at least 12 months before. Socio-demographic details, patient-reported outcomes and the history of diagnosis were obtained via a structured questionnaire.

Results: The average diagnostic latency for this group of patients with Sjögren's syndrome is 5.98 years, with a median of 2 years. The cohort was divided into two groups based on the median of two years: one with a longer and the other with a shorter diagnostic delay. The group with a longer diagnostic delay was in a significantly poorer general health condition and was significantly more likely to report a negative impact on the general performance. Patients with longer diagnostic delay reported significantly more physician visits and suffered significantly more frequently from vaginal dryness, gastrointestinal symptoms and breathlessness as initial symptoms.

Conclusions: Our findings underline the importance of awareness of Sjögren's syndrome and interdisciplinary training of physicians to improve the patient related outcomes due to a reduced diagnostic latency.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
时间对原发性Sjögren综合征患者诊断的影响:一项横断面研究。
目的:原发性Sjögren综合征是一种慢性自身免疫性疾病,伴有外分泌腺炎症。由于经常出现非特异性症状,如疲劳和肌痛,因此很难诊断。本研究的目的是调查患者在诊断为原发性Sjögren综合征之前的经历,以及这如何影响患者报告的结果。方法:研究纳入170例年龄≥18岁的门诊患者,诊断为原发性Sjögren综合征(ICD-10 M35.0),至少12个月前符合ACR/EULAR 2016标准。社会人口学细节、患者报告的结果和诊断史通过结构化问卷获得。结果:该组Sjögren综合征患者的平均诊断潜伏期为5.98年,中位数为2年。该队列根据中位数为两年分为两组:一组诊断延迟较长,另一组诊断延迟较短。诊断延迟较长的一组总体健康状况明显较差,并且更有可能报告对总体表现的负面影响。诊断延迟时间较长的患者报告的医生就诊次数明显更多,并且阴道干燥、胃肠道症状和呼吸困难作为初始症状的频率明显更高。结论:我们的研究结果强调了对Sjögren综合征的认识和医生的跨学科培训的重要性,因为减少了诊断潜伏期,可以改善患者相关的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.10
自引率
18.90%
发文量
377
审稿时长
3-6 weeks
期刊介绍: Clinical and Experimental Rheumatology is a bi-monthly international peer-reviewed journal which has been covering all clinical, experimental and translational aspects of musculoskeletal, arthritic and connective tissue diseases since 1983.
期刊最新文献
Cluster analysis identifies the differential impact of disease activity and severity on functional status and patient satisfaction in rheumatoid arthritis: the FRANK registry. Survival and early outcomes following lung transplantation for interstitial lung disease associated with non-scleroderma connective tissue disease: a national cohort study. A Phase 3, 28-week, multicentre, randomised, double-blind, placebo-controlled trial (OA-10) to evaluate the efficacy and safety of a single injection of lorecivivint in the target knee joint of moderately to severely symptomatic osteoarthritis patients. Phase 3, 56-week, randomised, double-blind, placebo-controlled study utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis: OA-11 Study. The association between radiographic progression, functional impairment, markers of dyslipidaemia and inflammation in patients with hand osteoarthritis: a five-year longitudinal study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1